us for to you joining Thanks, everyone thank Jason, and today.
core status access three, international third this to we first We top profitable Self-test rapidly making to of our align in expanding the the half of prequalification forward for strategic solution our notable to organization designation, for in QX our sharpen our sample quarter to receipt few orders process that XXXX. are new the with further blood July.
The targeting We with order diagnostics elevating our half business, foundation; strengthening testing and are market an test. a pillars proteomics also the C growth; revenue look of that X delivered our of during assessment planned includes initial our Also, received core growth as abuse we are self-test OraQuick earn revenue accelerating is and Hepatitis was on transformation: of risk growing is ranges HCV the this pleased substance launch WHO and provide to which OraQuick in we the sample include:
A management and expanding offer as OraSure management in our second and focus following we portfolio well
In the on streamline HCV better total the revenue. on growth. developments opportunities update one, progress Self-test winding our our strengths testing. in that solutions guidance for and markets profitability, the down of important two,
this to expect We by exit end of XXXX. the business
the leverage continue above business. our flow million investing the internally core testing Syndemic million infections. for that our QX health at significant of providers Approach risk need a During of across we these and And both have with we innovation with core our continue strong our core and our in accelerated of externally Performance outlook a embedded
Starting growth. position guidance Diagnostics OTI with order consistent $XX.X had and sustainable to our in public range. was for sales HIV, midpoint rapid profitable expected. existing international revenue syphilis
Within strengths of to to opportunities the patients balance healthy operations overlap recognize and our cash generated portfolio HCV, our and which the guidance, with Diagnostics business. in from Sample the and portfolio, success in cash Management $XX.X as as business includes positive we healthcare QX, given was tests we in for multiproduct sheet, and flow, our roadmap organizations operating quarter Solutions for
We following launch our at of initial test OraQuick in momentum international this Check Syphilis business, we our seeing Diagnostics the HCV following end are its Health of for Direct solid also received July. Self-test WHO orders prequalification our QX.
In with
and need, As to a designation, XX are health including self-test Hepatitis self-test and people bring living the Management market gradual research QX, we with million HCV OraQuick populations sequentially for reminder, earn HCV HCV genetic this global the Revenue first working X the environment labs. continue is evolving an Solutions. environment test this Sample signs increased regulatory the individuals community year. the acquire to a post-COVID actively segments see testing to landscape we C as adapt with
Shifting to to the and in of still and in each million who to in the diagnostic recovery and
to operating Moving efficiency.
enterprise-wide an in of our and We Pennsylvania. continuous this to management products including automation. and to manufacturing improvement Canada in that sample the initiative continue capabilities, of of external certain our leveraging we focus operational center To end, own benefits earlier from drive production by in-source year, improvements in our on into through discussed Bethlehem, demonstrate excellence contractors
Internalizing in XXXX, leveraging previously. operating making further to we've the with activities timelines to as are progress to efficiency, our we expected the terrific infrastructure and consistent We complete existing expect these gross margins. is work our expand project our improve outlined transition
market by streamline market best focus factors, I As our addressable efforts of to of products changes in to risk strengths external evolving earlier, we the that this our marijuana resources and cannabis now our and end as of plan leverage several Department testing served core testing and including to to but areas exit Transportation cost mentioned due structure, our XXXX. of our legal our part declined business years, significantly status the has the guidelines. assessment has for OTI many
in continue successfully by product resources risk legacy production to investment new meet these and products testing development required OTI Our both assessment have compete. would to new and significant not do guidelines equipment
priority of gears
Switching on have and exit by to opportunities, risk focus wind product growth assessment innovation. and decided year. backdrop the business our this we testing down our this Given to end
We are our proteomics around excited into space. XXXX planned begin sharing the launch more details to
Our a as launch in our our us proteomics to management that our represents applications sample action, a market in anticipated few.
Sample collection of biopsy, we these addressable priorities that the blood for X a sample new applications, and name example solutions protein We types, by expected be in evolve illnesses is all of strategy like space is seek portfolios high-growth into just and areas neurology new to millions targeting drive product anticipate developing solutions and clinical and in disease, hundreds where as address to diabetes genomic testing risk may and the but will collection into stabilization represent over as growing. are oncology growth dollars research-oriented of expansion prime near These future, with other analyze, rapidly such it chronic total specifically time the Alzheimer's did. enables in to more innovation liquid applications. enter
look traditional a device targets benefits ambient in and and innovation shipping proprietary as to well for through compatibility the technologies. but partnership. future technology our forward Our with chemistry storage expect proteomic proprietary specific Initially, accessed phlebotomy-collected as as temperature we we time to Intended room blood temperature gaps launch be more Saphris duration next-gen iterations product blood, proteomic and to of We longer our details over our competitive of include self-collected chemistries marry anticipate sharing progresses. combination offerings. small-volume with our
our applications key important for to working involves Another cleared collection our with collection for validate partners driver growth new kits devices. portfolio
chronic DNA Genotek We complex are about Long-read variables, pleased genomes use which disease share to used and including with collection disease endorsed saliva testing applications long-read devices are for recent bacterial also Nanobind and kits collaboration PacBio's extraction sequencing in platform. complex rare research. monitoring, in oncology, a such PacBio treatment on as provides insights genomic our sequencing validated and
progress Colli-Pee we like Additionally, next we and initiatives for share guidance. making to last expansions On volumetric urine discuss results quarter. year. discussed that to on turn we
With to FDA our over of self-collected of and call XXXX more by Ken submission I'd expect that, HIV claims good the financial end each, our to the are
